Drug intelligence / Profile preview

GATE-102

Development stage
Unknown
Lead developer
Gate Neurosciences
Modality
Small Molecules
Administration
Oral
01

Overview

GATE-102 is an orally bioavailable small molecule that acts as a positive allosteric modulator (PAM) of the N-methyl-D-aspartate (NMDA) receptor. Originally developed by Allergan (later AbbVie) as AGN-241751 and subsequently acquired by Gate Neurosciences, the compound is designed to enhance synaptic plasticity and restore dendritic spine density, which are often diminished in patients with neuropsychiatric conditions. Unlike NMDA antagonists such as ketamine, GATE-102's mechanism as a PAM aims to provide rapid and sustained antidepressant effects with an improved safety profile, specifically avoiding the dissociative and sedative side effects associated with receptor blockade. It is currently being developed for the treatment of major depressive disorder (MDD).

Other names
AGN 241751AGN241751AGN-241751
02

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on GATE-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on GATE-102.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call